“
“Objective: The aim of this study was to evaluate early cardiac abnormalities in obese children by the conventional echocardiography and to verify whether N-terminal pro B-type natriuretic peptide (NT-proBNP) differ between obese and
healthy children.
Methods: We started this study with 68 obese children and 35 healthy controls matched for age and sex. Body mass index (BMI) was calculated. Children with a BMI >= 95th percentile were considered obese. Thirty children in the obese group were also diagnosed with metabolic syndrome, according to the International Diabetes Federation criteria. Standard CX-6258 in vivo echocardiographic study was performed on each patient and control subject. Diastolic filling parameters were evaluated using pulsed-wave tissue Doppler method. Blood samples were taken at 8 a. m. to study blood biochemistry tests, including insulin, lipids, glucose, and
NT-proBNP. Serum NT-proBNP levels were measured by 5-Fluoracil supplier a solid-phase, enzyme-labeled chemiluminescent immunometric assay. Homeostasis model assessment of insulin resistance (HOMA-IR) was calculated. Children with HOMA-IR >3.16 were considered insulin-resistant.
Results: There were diastolic filling abnormalities in obese children, as shown by a decreased mitral valve early filling (E) wave/late filling (A) ratio and a prolongation in E-wave deceleration time. The levels of NT-proBNP were not statistically different among the groups. The levels of NT-proBNP were not different between obese children with and without metabolic syndrome, those with and without hypertension, and those with and without insulin resistance, respectively.
Conclusion: Although there were diastolic filling abnormalities in obese children, their NT-proBNP levels were not different from healthy controls. It seems that there is no diagnostic value in NT-proBNP levels between obese children and healthy controls”
“Statins are used widely for the treatment of cardiovascular (CV) disease because they improve
the lipid profile and reduce the rate of coronary and cerebrovascular diseases. During the past 15 years, the overall risk profile of patients treated with statins has changed considerably, becoming more complex due to a progressive increase R788 clinical trial in the proportion of subjects with several concomitant diseases. Indeed, the presence of dyslipidemia is frequently associated with arterial hypertension, diabetes and the metabolic syndrome, as well as with CV and renal disease. In this patient population, the ideal statin should bear some properties that allow for both a substantial improvement in the lipid profile and a reduction in global CV risk. In particular, the ideal statin should provide both a reduction in total and LDL-C and an increase in HDL-C, effects that have been described for statins such as pitavastatin.